Jason O’byrne Sells 6,799 Shares of Vir Biotechnology (NASDAQ:VIR) Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) CFO Jason O’byrne sold 6,799 shares of the stock in a transaction on Monday, November 17th. The shares were sold at an average price of $5.56, for a total value of $37,802.44. Following the sale, the chief financial officer directly owned 110,701 shares in the company, valued at $615,497.56. This trade represents a 5.79% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Vir Biotechnology Stock Performance

VIR opened at $5.44 on Thursday. The stock has a market capitalization of $756.81 million, a P/E ratio of -1.51 and a beta of 1.27. The company’s 50-day simple moving average is $5.60 and its two-hundred day simple moving average is $5.27. Vir Biotechnology, Inc. has a 52-week low of $4.16 and a 52-week high of $14.45.

Vir Biotechnology (NASDAQ:VIR) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($1.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.47). Vir Biotechnology had a negative return on equity of 50.76% and a negative net margin of 2,963.54%.The company had revenue of $0.24 million during the quarter, compared to the consensus estimate of $1.98 million. During the same quarter in the prior year, the firm earned ($1.56) earnings per share. The business’s revenue was up .8% compared to the same quarter last year. Research analysts forecast that Vir Biotechnology, Inc. will post -3.92 EPS for the current fiscal year.

Wall Street Analyst Weigh In

VIR has been the subject of a number of research analyst reports. Bank of America raised shares of Vir Biotechnology from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $12.00 to $14.00 in a research report on Wednesday, August 27th. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Vir Biotechnology in a report on Monday, September 15th. Evercore ISI initiated coverage on Vir Biotechnology in a research report on Wednesday, September 3rd. They set an “outperform” rating and a $12.00 price objective for the company. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Vir Biotechnology in a research report on Wednesday, November 5th. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Vir Biotechnology has an average rating of “Moderate Buy” and an average target price of $17.30.

Institutional Investors Weigh In On Vir Biotechnology

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Connective Capital Management LLC purchased a new position in Vir Biotechnology during the third quarter valued at $431,000. Sender Co & Partners Inc. bought a new position in shares of Vir Biotechnology in the third quarter worth about $247,000. Dark Forest Capital Management LP bought a new position in shares of Vir Biotechnology in the third quarter worth about $817,000. XTX Topco Ltd purchased a new position in shares of Vir Biotechnology during the 3rd quarter valued at about $799,000. Finally, Prelude Capital Management LLC bought a new position in shares of Vir Biotechnology during the 3rd quarter valued at approximately $108,000. 65.32% of the stock is currently owned by hedge funds and other institutional investors.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).